Nanobiotix S.A. (NBTX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $35.33: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality; Negative price momentum.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used... Read more
Sell if holding. Engine safety override at $35.33: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 110d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-12Recent Developments — Nanobiotix S.A.
Latest news
- NEWS Leerink Partners Maintains Outperform on Nanobiotix, Raises Price Target to $46 — benzinga Jun 4, 2026 positive
- NEWS Nanobiotix Reports Q1 2026 Progress, Highlights 85.7% Response Rate In Phase 2 JNJ-1900 NSCLC Study, FDA Acceptance Of N — benzinga Jun 2, 2026 positive
- NEWS Nanobiotix Added to Euronext Tech Leaders Program and Index — benzinga Jun 2, 2026 positive
- NEWS Reported Earlier, Nanobiotix Launches ~€75M ($87M) Global Follow-On Offering Of ADSs And Ordinary Shares To Advance Nano — benzinga May 21, 2026 positive
- NEWS 12 Health Care Stocks Moving In Wednesday's After-Market Session — benzinga May 20, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -73.5%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $35.33: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $32.86. Score 5.6/10, moderate confidence.
Take-profit target: $37.12 (+5.1% upside). Prior stop was $32.86. Stop-loss: $32.86.
Quality below floor (3.5 < 4.0).
Nanobiotix S.A. trades at a P/E of N/A (forward 430.1). TrendMatrix value score: 4.6/10. Verdict: Sell.
12 analysts cover NBTX with a consensus score of 4.2/5. Average price target: $43.
What does Nanobiotix S.A. do?Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the...
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.